Bank of New York Mellon Corp Has $951,000 Position in Omada Health, Inc. $OMDA

Key Points

• Bank of New York Mellon increased its Omada Health stake by 284.5% in the first quarter, owning 75,681 shares valued at approximately $951,000.
• Omada Health’s second-quarter results exceeded expectations, with adjusted earnings of $0.08 per share versus a projected $0.02 loss and revenue of $87.8 million versus the $80.9 million consensus estimate.
• Despite a “Moderate Buy” analyst consensus and a $25.75 average price target, valuation and insider-selling risks remain: the stock trades near its 52-week high with a P/E ratio above 475, while insiders sold roughly 254,700 shares over the past three months.

Bank of New York Mellon Corp raised its position in Omada Health, Inc. (NASDAQ:OMDA - Free Report) by 284.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 75,681 shares of the company's stock after acquiring an additional 55,996 shares during the period. Bank of New York Mellon Corp owned about 0.13% of Omada Health worth $951,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of OMDA. Quarry LP acquired a new position in Omada Health during the fourth quarter valued at approximately $29,000. TD Waterhouse Canada Inc. bought a new stake in shares of Omada Health during the 4th quarter worth approximately $32,000. Raymond James Financial Inc. acquired a new stake in shares of Omada Health in the 2nd quarter valued at approximately $32,000. Strs Ohio boosted its holdings in shares of Omada Health by 151.0% in the 4th quarter. Strs Ohio now owns 4,267 shares of the company's stock valued at $67,000 after buying an additional 2,567 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new position in shares of Omada Health in the fourth quarter valued at $73,000.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q2 results exceeded expectations. Omada reported adjusted earnings of $0.08 per share, compared with analysts’ expectation of a $0.02 loss, while revenue of approximately $87.8 million topped the $80.9 million consensus estimate. The results suggest growth in its digital chronic-care platform is increasingly converting into profitability. Omada Health Q2 earnings analysis
• Positive Sentiment: Several analysts raised their targets. Robert W. Baird lifted its price target from $15 to $25, while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG. The broader analyst consensus remains “Moderate Buy,” with an average target around $25.67–$25.75.
• Positive Sentiment: Institutional ownership increased. Perceptive Advisors and BlackRock reportedly initiated positions, Millennium Management expanded its stake, and Versant Capital Management increased its holdings by more than 300%. These moves may reinforce investor confidence in Omada’s growth outlook.
• Neutral Sentiment: Baird’s neutral stance highlights limited near-term upside. Its $25 target is only modestly above the recent trading level, suggesting the earnings beat and growth prospects may already be substantially reflected in the stock price.
• Negative Sentiment: Multiple senior executives sold shares. CEO Sean Duffy sold 8,628 shares, CFO Steven Cook sold 16,842 shares across two transactions, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. Although these sales may reflect personal liquidity or compensation planning, concentrated selling near $25 can weigh on sentiment. Omada Health insider trading report
• Negative Sentiment: Valuation risk remains elevated. Omada’s market capitalization is approximately $1.5 billion, while its reported price-to-earnings ratio is above 475. With the shares close to their 52-week high, any slowdown in revenue growth or profitability could prompt profit-taking.

Insider Activity at Omada Health

In related news, CFO Steven L. Cook sold 33,000 shares of Omada Health stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $19.89, for a total transaction of $656,370.00. Following the sale, the chief financial officer directly owned 133,359 shares in the company, valued at $2,652,510.51. This trade represents a 19.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sean P. Duffy sold 25,886 shares of Omada Health stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $22.68, for a total transaction of $587,094.48. Following the transaction, the chief executive officer owned 411,861 shares in the company, valued at approximately $9,341,007.48. This trade represents a 5.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 254,726 shares of company stock valued at $5,370,496. 6.38% of the stock is owned by insiders.

Omada Health Stock Up 2.2%

NASDAQ OMDA opened at $24.37 on Friday. The firm has a 50-day moving average price of $20.87 and a two-hundred day moving average price of $16.43. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92. The company has a market capitalization of $1.49 billion, a P/E ratio of 487.40 and a beta of 1.73.

Omada Health (NASDAQ:OMDA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.10. Omada Health had a return on equity of 2.67% and a net margin of 1.39%.The company had revenue of $87.83 million for the quarter, compared to analysts' expectations of $80.93 million. Equities analysts expect that Omada Health, Inc. will post -0.01 EPS for the current year.

Wall Street Analyst Weigh In

OMDA has been the subject of a number of recent analyst reports. Barclays increased their price target on shares of Omada Health from $20.00 to $25.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. BMO Capital Markets reaffirmed an "outperform" rating and issued a $24.00 target price on shares of Omada Health in a report on Friday, August 7th. Citigroup reiterated an "outperform" rating on shares of Omada Health in a research note on Monday, July 20th. The Goldman Sachs Group reiterated a "buy" rating on shares of Omada Health in a report on Friday, May 8th. Finally, Citizens Jmp boosted their price target on Omada Health from $21.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Monday, July 20th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $25.75.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Want to see what other hedge funds are holding OMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omada Health, Inc. (NASDAQ:OMDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source